{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:36:36Z","timestamp":1793316996048,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1245\/s10434-025-17009-1","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T02:42:20Z","timestamp":1739846540000},"page":"4408-4416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Minimum Requirements to Safely Establish and Sustain New Hepatic Arterial Infusion Pump Programs: An International Expert Perspective"],"prefix":"10.1245","volume":"32","author":[{"given":"Ryan P.","family":"Merkow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cavnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye C.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Karanicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas Groot","family":"Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein Y. V.","family":"Homs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise C.","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Helft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blase N.","family":"Polite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope E.","family":"Uronis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"D\u2019Angelica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Lidsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"17009_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jamcollsurg.2020.11.013","volume":"232","author":"R Anteby","year":"2021","unstructured":"Anteby R, et al. Getting chemotherapy directly to the liver: the historical evolution of hepatic artery chemotherapy. J Am Coll Surg. 2021;232:332\u20138. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2020.11.013.","journal-title":"J Am Coll Surg."},{"key":"17009_CR2","first-page":"176","volume":"10","author":"WD Ensminger","year":"1983","unstructured":"Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Seminars in oncology. 1983;10:176\u201382.","journal-title":"Seminars in oncology."},{"key":"17009_CR3","first-page":"3784","volume":"38","author":"WD Ensminger","year":"1978","unstructured":"Ensminger WD, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2\u2019-deoxyuridine and 5-fluorouracil. Cancer Res. 1978;38:3784\u201392.","journal-title":"Cancer Res."},{"key":"17009_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/SLA.0000000000005434","volume":"276","author":"JM Sharib","year":"2022","unstructured":"Sharib JM, et al. Hepatic artery infusion pumps: a surgical toolkit for intraoperative decision-making and management of hepatic artery infusion-specific complications. Ann Surg. 2022;276:943\u201356. https:\/\/doi.org\/10.1097\/SLA.0000000000005434.","journal-title":"Ann Surg"},{"key":"17009_CR5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/01.SLA.0000071561.76384.19","volume":"237","author":"M Onaitis","year":"2003","unstructured":"Onaitis M, et al. Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. Ann Surg. 2003;237:782\u20138. https:\/\/doi.org\/10.1097\/01.SLA.0000071561.76384.19.","journal-title":"Ann Surg."},{"key":"17009_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","volume":"261","author":"MI D'Angelica","year":"2015","unstructured":"D\u2019Angelica MI, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261:353\u201360. https:\/\/doi.org\/10.1097\/SLA.0000000000000614.","journal-title":"Ann Surg."},{"key":"17009_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.7326\/0003-4819-107-4-459","volume":"107","author":"N Kemeny","year":"1987","unstructured":"Kemeny N, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial Ann Intern Med. 1987;107:459\u201365. https:\/\/doi.org\/10.7326\/0003-4819-107-4-459.","journal-title":"A randomized trial. Ann Intern Med."},{"key":"17009_CR8","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1200\/JCO.2001.19.10.2687","volume":"19","author":"N Kemeny","year":"2001","unstructured":"Kemeny N, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol. 2001;19:2687\u201395. https:\/\/doi.org\/10.1200\/JCO.2001.19.10.2687.","journal-title":"J Clin Oncol."},{"key":"17009_CR9","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1200\/JCO.2005.07.100","volume":"23","author":"N Kemeny","year":"2005","unstructured":"Kemeny N, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23:4888\u201396. https:\/\/doi.org\/10.1200\/JCO.2005.07.100.","journal-title":"J Clin Oncol."},{"key":"17009_CR10","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","volume":"27","author":"NE Kemeny","year":"2009","unstructured":"Kemeny NE, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27:3465\u201371. https:\/\/doi.org\/10.1200\/JCO.2008.20.1301.","journal-title":"J Clin Oncol."},{"key":"17009_CR11","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","volume":"24","author":"NE Kemeny","year":"2006","unstructured":"Kemeny NE, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24:1395\u2013403. https:\/\/doi.org\/10.1200\/JCO.2005.03.8166.","journal-title":"J Clin Oncol."},{"key":"17009_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/jso.24898","volume":"117","author":"LM Pak","year":"2018","unstructured":"Pak LM, et al. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. J Surg Oncol. 2018;117:634\u201343. https:\/\/doi.org\/10.1002\/jso.24898.","journal-title":"J Surg Oncol."},{"key":"17009_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/jso.24399","volume":"114","author":"A Cercek","year":"2016","unstructured":"Cercek A, et al. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J Surg Oncol. 2016;114:655\u201363. https:\/\/doi.org\/10.1002\/jso.24399.","journal-title":"J Surg Oncol."},{"key":"17009_CR14","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.2016.71.8346","volume":"35","author":"B Groot Koerkamp","year":"2017","unstructured":"Groot Koerkamp B, et al. Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis. J Clin Oncol. 2017;35:1938\u201344. https:\/\/doi.org\/10.1200\/JCO.2016.71.8346.","journal-title":"J Clin Oncol."},{"key":"17009_CR15","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJM199912303412702","volume":"341","author":"N Kemeny","year":"1999","unstructured":"Kemeny N, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039\u201348. https:\/\/doi.org\/10.1056\/NEJM199912303412702.","journal-title":"N Engl J Med."},{"key":"17009_CR16","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1200\/JCO.2003.03.142","volume":"21","author":"N Kemeny","year":"2003","unstructured":"Kemeny N, et al. Phase I\/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol. 2003;21:3303\u20139. https:\/\/doi.org\/10.1200\/JCO.2003.03.142.","journal-title":"J Clin Oncol."},{"key":"17009_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/jso.24189","volume":"113","author":"NE Kemeny","year":"2016","unstructured":"Kemeny NE, et al. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol. 2016;113:477\u201384. https:\/\/doi.org\/10.1002\/jso.24189.","journal-title":"J Surg Oncol."},{"key":"17009_CR18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJM200502173520723","volume":"352","author":"NE Kemeny","year":"2005","unstructured":"Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005;352:734\u20135. https:\/\/doi.org\/10.1056\/NEJM200502173520723.","journal-title":"N Engl J Med."},{"key":"17009_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2020","unstructured":"Cercek A, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6:60\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3718.","journal-title":"JAMA Oncol."},{"key":"17009_CR20","unstructured":"Lidsky ME, Cercek A, Maithel SK, Kemeny N, D\u2019Angelica MI. Hepatic arterial infusion pump chemotherapy: is it ready for prime time in the United States? ASCO daily news: clinical news from the American society of clinical oncology. 13 Apr 2023. Available at: <https:\/\/dailynews.ascopubs.org\/do\/hepatic-arterial-infusion-pump-chemotherapy-ready-prime-time-united-states>."},{"key":"17009_CR21","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1245\/s10434-019-07973-w","volume":"26","author":"FE Buisman","year":"2019","unstructured":"Buisman FE, et al. Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases: results of a safety and feasibility study in the netherlands. Ann Surg Oncol. 2019;26:4599\u2013607. https:\/\/doi.org\/10.1245\/s10434-019-07973-w.","journal-title":"Ann Surg Oncol."},{"key":"17009_CR22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/jso.25249","volume":"118","author":"J Chakedis","year":"2018","unstructured":"Chakedis J, et al. Implementation and early outcomes for a surgeon-directed hepatic arterial infusion pump program for colorectal liver metastases. J Surg Oncol. 2018;118:1065\u201373. https:\/\/doi.org\/10.1002\/jso.25249.","journal-title":"J Surg Oncol."},{"issue":"13","key":"17009_CR23","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1245\/s10434-020-08972-y","volume":"27","author":"JM Creasy","year":"2020","unstructured":"Creasy JM, et al. Implementation of a hepatic artery infusion program: initial patient selection and perioperative outcomes of concurrent hepatic artery infusion and systemic chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2020;27(13):5086\u201395. https:\/\/doi.org\/10.1245\/s10434-020-08972-y.","journal-title":"Ann Surg Oncol."},{"key":"17009_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1245\/s10434-016-5418-6","volume":"24","author":"M Dhir","year":"2017","unstructured":"Dhir M, et al. Hepatic arterial infusion in combination with modern systemic chemotherapy is associated with improved survival compared with modern systemic chemotherapy alone in patients with isolated unresectable colorectal liver metastases: a case-control study. Ann Surg Oncol. 2017;24:150\u20138. https:\/\/doi.org\/10.1245\/s10434-016-5418-6.","journal-title":"Ann Surg Oncol."},{"key":"17009_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/jso.26270","volume":"123","author":"H Muaddi","year":"2021","unstructured":"Muaddi H, et al. Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: a multicenter, retrospective cohort study. J Surg Oncol. 2021;123:252\u201360. https:\/\/doi.org\/10.1002\/jso.26270.","journal-title":"J Surg Oncol."},{"key":"17009_CR26","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.amjsurg.2021.10.032","volume":"223","author":"MP O'Leary","year":"2022","unstructured":"O\u2019Leary MP, et al. Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases. Am J Surg. 2022;223:1151\u20136. https:\/\/doi.org\/10.1016\/j.amjsurg.2021.10.032.","journal-title":"Am J Surg."},{"key":"17009_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/jso.26911","volume":"126","author":"BS Walker","year":"2022","unstructured":"Walker BS, et al. Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: outcomes in a newly established program. J Surg Oncol. 2022;126:513\u201322. https:\/\/doi.org\/10.1002\/jso.26911.","journal-title":"J Surg Oncol."},{"issue":"2","key":"17009_CR28","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1245\/s10434-024-16488-y","volume":"32","author":"A Liu","year":"2025","unstructured":"Liu A, et al. Perioperative and oncologic outcomes of hepatic arterial infusion (HAI) pump chemotherapy for patients with unresectable colorectal liver metastases at an expanding HAI program. Ann Surg Oncol. 2025;32(2):1033\u201342. https:\/\/doi.org\/10.1245\/s10434-024-16488-y.","journal-title":"Ann Surg Oncol."},{"key":"17009_CR29","unstructured":"National Institutes of Health. Testing pump chemotherapy in addition to standard of care chemotherapy versus standard of care chemotherapy alone for patients with unresectable colorectal liver metastases: the PUMP trial. ClinicalTrials.gov identifier: NCT05863195. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/history\/NCT05863195"},{"key":"17009_CR30","unstructured":"National Institutes of Health. HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden (EXCALIBUR1+2). ClinicalTrials.gov identifier: NCT04898504. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04898504."},{"key":"17009_CR31","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.hpb.2022.08.008","volume":"24","author":"M Cavnar","year":"2022","unstructured":"Cavnar M, et al. Considerations and barriers to starting a new HAI pump program: an international survey of the HAI consortium research network. HPB (Oxford). 2022;24:2104\u201311. https:\/\/doi.org\/10.1016\/j.hpb.2022.08.008.","journal-title":"HPB (Oxford)."},{"key":"17009_CR32","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.hpb.2023.12.006","volume":"26","author":"LM Janczewski","year":"2024","unstructured":"Janczewski LM, et al. Safety and feasibility of establishing an adjuvant hepatic artery infusion program. HPB (Oxford). 2024;26:656\u201363. https:\/\/doi.org\/10.1016\/j.hpb.2023.12.006.","journal-title":"HPB (Oxford)."},{"key":"17009_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.surg.2023.03.026","volume":"174","author":"HG McDonald","year":"2023","unstructured":"McDonald HG, et al. Starting a successful hepatic artery infusion pump program: a practical guide. Surgery. 2023;174:101\u20135. https:\/\/doi.org\/10.1016\/j.surg.2023.03.026.","journal-title":"Surgery."},{"key":"17009_CR34","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1245\/s10434-023-14519-8","volume":"31","author":"HG McDonald","year":"2024","unstructured":"McDonald HG, et al. Phase I safety and feasibility pilot of hepatic artery infusion chemotherapy in a rural catchment area using the codman vascular catheter with the medtronic synchromed II pump for intrahepatic cancers. Ann Surg Oncol. 2024;31:1252\u201363. https:\/\/doi.org\/10.1245\/s10434-023-14519-8.","journal-title":"Ann Surg Oncol."},{"key":"17009_CR35","doi-asserted-by":"publisher","first-page":"7362","DOI":"10.1245\/s10434-023-14207-7","volume":"30","author":"SJ Judge","year":"2023","unstructured":"Judge SJ, et al. Current practices in hepatic artery infusion (HAI) chemotherapy: an international survey of the HAI consortium research network. Ann Surg Oncol. 2023;30:7362\u201370. https:\/\/doi.org\/10.1245\/s10434-023-14207-7.","journal-title":"Ann Surg Oncol."},{"key":"17009_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jamcollsurg.2005.03.019","volume":"201","author":"PJ Allen","year":"2005","unstructured":"Allen PJ, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201:57\u201365. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2005.03.019.","journal-title":"J Am Coll Surg."},{"key":"17009_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1245\/s10434-023-14515-y","volume":"31","author":"LM Janczewski","year":"2024","unstructured":"Janczewski LM, Ellis RJ, Lidsky ME, D\u2019Angelica MI, Merkow RP. Hepatic artery infusion chemotherapy: a quality framework. Ann Surg Oncol. 2024;31:701\u20134. https:\/\/doi.org\/10.1245\/s10434-023-14515-y.","journal-title":"Ann Surg Oncol."},{"key":"17009_CR38","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1245\/s10434-011-2102-8","volume":"19","author":"K Ito","year":"2012","unstructured":"Ito K, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol. 2012;19:1609\u201317. https:\/\/doi.org\/10.1245\/s10434-011-2102-8.","journal-title":"Ann Surg Oncol."},{"key":"17009_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/OP.23.00374","volume":"20","author":"D Rao","year":"2024","unstructured":"Rao D, Ellis CS, Kemeny N, Cercek A. Case-based clinical guidance on dosing and management of the hepatic artery infusion chemotherapy pump. JCO Oncol Pract. 2024;20:187\u201394. https:\/\/doi.org\/10.1200\/OP.23.00374.","journal-title":"JCO Oncol Pract."},{"key":"17009_CR40","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1148\/rg.2021200130","volume":"41","author":"KJ Napier","year":"2021","unstructured":"Napier KJ, Lidsky ME, James OG, Wildman-Tobriner B. Hepatic arterial infusion pumps: what the radiologist needs to know. Radiographics. 2021;41:895\u2013908. https:\/\/doi.org\/10.1148\/rg.2021200130.","journal-title":"Radiographics."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17009-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:14:37Z","timestamp":1746288877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17009-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["17009"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17009-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ryan P. Merkow: Relevant financial activities outside the submitted work (Intera Oncology). Louise C. Connell: Consultancy work (Intera Oncology). Bas Groot Koerkamp: In-kind contribution of pumps for a clinical trial investigating HAI (Tricumed), and support for clinical trials investigating HAI (Intera). Andrea Cercek: Relevant financial activities outside the submitted work (Abbvie, Amgen, Agenus, Daiichi Saynko, Merck, GSK, Pfizer, Regenen, Janssen, and Roche). Pending patents: Neoadjuvant PD-1 blockade for mismatch repair-deficient solid tumors; HAI liver-directed therapy for colorectal liver metastases in patients with DPD deficiency. Blase N. Polite: Speaking and consulting (Natera). Michael J. Cavnar, Ana L. Gleisner, Skye C. Mayo, Sepideh Gholami, Paul J. Karanicolas, Marjolein Y.V. Homs, Paul R. Helft, Reema A. Patel, Hope E. Uronis, Michael D\u2019Angelica, and Michael E. Lidsky have no disclosures to declare that may be relevant to the contents of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}